| Arsenic induces fibrogenic changes in human kidney epithelial cells potentially through epigenetic alterations in DNA methylation YW Chang, KP Singh Journal of cellular physiology 234 (4), 4713-4725, 2019 | 39 | 2019 |
| Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells L Ponnusamy, PKS Mahalingaiah, YW Chang, KP Singh European Journal of Pharmaceutical Sciences 123, 56-69, 2018 | 33 | 2018 |
| Nicotine-induced oxidative stress contributes to EMT and stemness during neoplastic transformation through epigenetic modifications in human kidney epithelial cells YW Chang, KP Singh Toxicology and applied pharmacology 374, 65-76, 2019 | 24 | 2019 |
| Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer KPS Logeswari Ponnusamy, Prathap Kumar S Mahalingaiah, Yu-Wei Chang Cancer Drug Resistance, 297-312, 2019 | 21 | 2019 |
| Arsenic-induced neoplastic transformation involves epithelial–mesenchymal transition and activation of the β-catenin/c-Myc pathway in human kidney epithelial cells YW Chang, KP Singh Chemical Research in Toxicology 32 (6), 1299-1309, 2019 | 12 | 2019 |
| Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells YW Chang, KP Singh PloS one 12 (3), e0174227, 2017 | 11 | 2017 |
| Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions CH Tsai, CH Li, PL Liao, YW Chang, YW Cheng, JJ Kang Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1867 (2), 118564, 2020 | 9 | 2020 |
| Duration-dependent effects of nicotine exposure on growth and AKT activation in human kidney epithelial cells YW Chang, KP Singh Molecular and Cellular Biochemistry 448 (1), 51-60, 2018 | 8 | 2018 |
| Genotoxicity tests of poly(styrene-co-maleic anhydride)-coated silver nanoparticles in vivo and in vitro YT Chen, JH Wu, FJ Tsai, YW Chang, SH Hsu, JJ Lin, HL Sue, JW Liao Journal of Experimental Nanoscience 10 (6), 449-457, 2015 | 6 | 2015 |
| CTNI-13. A FIRST-IN-HUMAN PHASE 0/1 TRIAL OF 5-AMINOLEVULINIC ACID SONODYNAMIC THERAPY (5-ALA SDT) IN RECURRENT GLIOBLASTOMA N Sanai, AC Tien, A Tovmasyan, YW Chang, T Margaryan, K Hendrickson, ... Neuro-Oncology 24 (Supplement_7), vii72-vii73, 2022 | 4 | 2022 |
| CTNI-48. A PHASE 0 ‘TRIGGER’TRIAL OF CDK4/6 PLUS ERK1/2 INHIBITORS IN RECURRENT GLIOBLASTOMA N Sanai, YW Chang, T Margaryan, A DeSantis, M Elliott, ... Neuro-Oncology 23 (Supplement_6), vi70-vi71, 2021 | 3 | 2021 |
| CTNI-23. A FIRST-IN-HUMAN PHASE 0/1 CLINICAL TRIAL OF 5-AMINOLEVULINIC ACID SONODYNAMIC THERAPY IN RECURRENT GLIOBLASTOMA N Sanai, AC Tien, A Tovmasyan, YW Chang, T Margaryan, K Hendrickson, ... Neuro-Oncology 23 (Supplement_6), vi64-vi64, 2021 | 2 | 2021 |
| 287MO A phase 0 ‘trigger’trial of pamiparib in newly diagnosed and recurrent glioblastoma patients N Sanai, SN Mehta, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, ... Annals of Oncology 33, S670, 2022 | 1 | 2022 |
| EXTH-09. TUMOR PHARMACOKINETICS, PHARMACODYNAMICS AND RADIATION SENSITIZATION IN PATIENT-DERIVED XENOGRAFT MODELS OF GLIOBLASTOMA TREATED WITH THE AURORA KINASE A INHIBITOR … S Mehta, A Tovmasyan, AC Tien, M Holter, B Hopkins, T Margaryan, ... Neuro-Oncology 23 (Supplement_6), vi165-vi165, 2021 | 1 | 2021 |
| Abstract CT125: A phase 0/2 ‘trigger’trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma N Sanai, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, J Harmon, ... Cancer Research 84 (7_Supplement), CT125-CT125, 2024 | | 2024 |
| Tumor pharmacokinetics and pharmacodynamics assessment of TEAD inhibitor VT03989 in patient-derived xenograft models of glioblastoma T Margaryan, YW Chang, J Molloy, B Hopkins, M Elliott, EL Melendez, ... Cancer Research 84 (6_Supplement), 1660-1660, 2024 | | 2024 |
| SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA K Johnson, AC Tien, J Jiang, J McNamara, YW Chang, C Montgomery, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| A Combined Phase 0/2" Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma WR Kennedy, YW Chang, J Jiang, J Molloy, C Pennington-Krygier, ... International Journal of Radiation Oncology, Biology, Physics 117 (2), e115, 2023 | | 2023 |
| Single nuclei RNAseq analysis of recurrent high-grade glioma tumors from patients in the phase 0/1 ‘trigger’trial of ribociclib plus everolimus N Sanai, AC Tien, K Johnson, J Jiang, YW Chang, C Montgomery, ... Cancer Research 83 (7_Supplement), 3404-3404, 2023 | | 2023 |
| Tumor pharmacokinetics, pharmacodynamics and efficacy analysis of WEE1 inhibitor, zn-c3 in patient-derived xenograft models of glioblastoma S Mehta, AC Tien, S Patel, T Margaryan, AT Shivanna, L Elena, J Molloy, ... Cancer Research 83 (7_Supplement), 2796-2796, 2023 | | 2023 |
Kamaleshwar P SinghTexas Tech UniversityEmail verificata su ttu.edu
Kamaleshwar P SinghTexas Tech UniversityEmail verificata su ttu.edu